3
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
22
Prostatic Neoplasms, Castration-Resistant
6
Neoplasm Metastasis
4
Breast Neoplasms
3
Neoplasms
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer
2
Hormone Refractory Prostate Cancer
2
Bone Metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
1
Fractures, Bone
1
Castration-resistant Prostate Cancer
1
Castrate-Resistant Prostate Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Bone Neoplasms
1
Bone Metastases
1
Bone Diseases
1
Interventions
Abiraterone Acetate
6
olaparib
5
Prednisone
5
enzalutamide
3
Prednisolone
3
radium Ra 223 dichloride
2
Pluvicto
2
niraparib
1
fludarabine
1
darolutamide
1
afuresertib
1
abiraterone
1
Docetaxel
1
Cyclophosphamide
1
Clinical Trials, Phase I as Topic
1
Blood Specimen Collection
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Castration-resistant Prostate Cancer
×
radium Ra 223 dichloride
×
Clear all
NCT02141438
2025-10-16
REASSURE
Bayer
Completed
1,472 enrolled
18 charts
NCT05301062
2023-09-22
CREDIT
Bayer
Terminated
8 enrolled